Bioactivity of isoflavones: assessment through a theoretical model as a way to obtain a "Theoretical Efficacy Related to Estradiol (TERE)".
The increase of human life span will have profound implications in Public Health in decades to come. By 2030, there will be an estimated 1.2 billion women in post-menopause. Hormone Replacement Therapy with synthetic hormones is still full of risks and according to the latest developments, should be used for the shortest time possible. Searching for alternative drugs is inevitable in this scenario and science must provide physicians with other substances that can be used to treat the same symptoms with less side effects. Systematic research carried out on this field of study is focusing now on isoflavones but the randomised controlled trials and reviews of meta-analysis concerning post-menopause therapy, that could have an important impact on human health, are very controversial. The aim of the present work was to establish a theoretical calculation suitable for use as a way to estimate the "Theoretical Efficacy (TE)" of a mixture with different bioactive compounds as a way to obtain a "Theoretical Efficacy Related to Estradiol (TERE)". The theoretical calculation that we propose in this paper integrates different knowledge about this subject and sets methodological boundaries that can be used to analyse already published data. The outcome should set some consensus for new clinical trials using isoflavones (isolated or included in mixtures) that will be evaluated to assess their therapeutically activity. This theoretical method for evaluation of a possible efficacy could probably also be applied to other herbal drug extracts when a synergistic or contradictory bio-effect is not verified. In this way, it we may contribute to enlighten and to the development of new therapeutic approaches.
da Graça R Campos
Maria
M
Center of Pharmaceutical Studies, University of Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal. mgcampos@ff.uc.pt <mgcampos@ff.uc.pt>
Matos
Miguel Pires
MP
D016208:Databases, Factual; D004958:Estradiol / Q000737:chemistry / Q000378:metabolism*; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000737:chemistry / Q000378:metabolism*; D008962:Models, Theoretical; D011485:Protein Binding; D011960:Receptors, Estrogen / Q000378:metabolism; D013025:Glycine max / Q000737:chemistry / Q000378:metabolism
D007529:Isoflavones; D011960:Receptors, Estrogen; D004958:Estradiol
Nutr Cancer. 1997;28(3):236-47
9343831
Maturitas. 2003 Mar 14;44 Suppl 1:S21-9
12609556
Maturitas. 2004 Aug 20;48(4):372-80
15283929
Vasc Med. 2004 Feb;9(1):26-30
15230485
Lancet. 1999 Oct 2;354(9185):1184
10513722
BMJ. 2001 Aug 11;323(7308):334-6
11498496
JAMA. 2004 Jul 7;292(1):65-74
15238592
Menopause. 2004 Jul-Aug;11(4):400-4
15243277
Am J Clin Nutr. 2005 Jan;81(1):5-6
15640453
Eur J Clin Nutr. 2003 Aug;57(8):889-94
12879082
Am J Med. 2003 Apr 15;114(6):470-6
12727580
Carcinogenesis. 2006 Jun;27(6):1292-9
16537557
Am J Clin Nutr. 2004 Feb;79(2):326-33
14749241
Atherosclerosis. 2002 Aug;163(2):339-47
12052481
Proc Nutr Soc. 2006 Feb;65(1):76-92
16441947
J Clin Endocrinol Metab. 1999 Mar;84(3):895-8
10084567
Am J Clin Nutr. 1984 Sep;40(3):569-78
6383008
J Clin Oncol. 2002 Jul 1;20(13):3040-1; author reply 3041-2
12089239
Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1066-71
12714433
Inflammopharmacology. 2008 Oct;16(5):227-9
18815739
Menopause. 2006 Sep-Oct;13(5):831-9
16932241
Chem Biol. 2004 Mar;11(3):397-406
15123269
Food Chem Toxicol. 2000 Jul;38(7):555-64
10942316
Am J Clin Nutr. 2003 Jul;78(1):123-30
12816781
J Bone Miner Res. 2002 Oct;17(10):1904-12
12369794
Lancet. 2000 Jan 15;355(9199):163-4
10675113
Obstet Gynecol. 1988 Nov;72(5):688-92
3140150
EMBO J. 1999 Sep 1;18(17):4608-18
10469641
J Clin Endocrinol Metab. 2001 Jul;86(7):3053-60
11443167